Exicure Reports Second Quarter 2019 Financial Results and Recent Developments

Exicure Reports Second Quarter 2019 Financial Results and Recent Developments

Publication date: Aug 09, 2019

CHICAGO CAMBRIDGE, Mass. –(BUSINESS WIRE)–Aug 8, 2019– Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today reported financial results for the second quarter ended June 30, 2019 and provided an update on corporate progress.

Second Quarter 2019 Financial Results and Financial Guidance Cash Position: As of June 30, 2019, Exicure had cash and cash equivalents of $17. 2 million compared to $26. 3 million as of December 31, 2018.

Cash Runway Guidance: Exicure believes that, based on its current operating plans and estimates of expenses, as of the date of this press release, its existing cash and cash equivalents will be sufficient to meet its anticipated cash requirements in excess of twelve months.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology.

Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: unexpected costs, charges or expenses that reduce cash runway; that Exicure’s pre-clinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials; that many drug candidates that have completed Phase 1 trials do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments; and the ability of Exicure to protect its intellectual property rights.

Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement (including without limitation its cash runway guidance) or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) June 30, 2019 December assets: Cash and cash revenue from related expenses and other current and equipment, noncurrent AND STOCKHOLDERS’ EQUITY Current liabilities: Current portion of long-term expenses and other current portion of deferred current debt, stock warrant noncurrent equity: Common stock, $0. 0001 par value per share; 200,000,000 shares authorized, 44,369,790 issued and outstanding, June 30, 2019; 44,358,000 issued and outstanding, December 31, paid-in stockholders’ liabilities and stockholders’ INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) Three Months Ended, June 30, Six Months Ended June and development and administrative operating income (expense), net: Interest income (loss), other income (loss), and diluted loss per common and diluted weighted-average common shares source version on Media Contacts: MacDougall Karen UNITED STATES NORTH AMERICA ILLINOIS MASSACHUSETTS INDUSTRY KEYWORD: ONCOLOGY HEALTH GENETICS CLINICAL TRIALS BIOTECHNOLOGY SOURCE: Exicure, Inc.

Concepts Keywords
AM Expense
AST Net operating loss
Ataxia Spherical nucleic acid
Balance Sheet Stage biotechnology
Bali Costs compensation travel
Biotechnology Biotechnology
Brain Economy
BUSINESS WIRE Articles
Business Wire
CAMBRIDGE
Cash Cash
Central Nervous System
CHICAGO
Chicago
Chief Executive Officer
Clinical Trial
Clinical Trials
Common Stock
Equity
Genetic Disorders
ILLINOIS
Immunotherapeutic
INC
Inflammatory Diseases
Intellectual Property
Liabilities
Nasdaq
Nasdaq Capital Market
Neurological
Neurology
NORTH AMERICA
Nucleic
Nucleic Acid
Oncology
Operating Income
Pipeline
Primate
Primates
Receptor
Runway
SEC
SNA
Spinocerebellar Ataxia
Underwriters
Weighted Average

Semantics

Type Source Name
gene UNIPROT SET
gene UNIPROT OTC
gene UNIPROT ELK3
gene UNIPROT CHAD
gene UNIPROT SLC6A2
gene UNIPROT EPHB1
disease DOID Batten disease
gene UNIPROT SLC17A5
gene UNIPROT TLR9
gene UNIPROT ATXN1
gene UNIPROT ATXN2
gene UNIPROT LY6E
disease DOID spinocerebellar ataxia type 3
gene UNIPROT ATXN3
disease MESH spinocerebellar ataxia type 3
disease MESH development
drug DRUGBANK Isoxaflutole
drug DRUGBANK Nonoxynol-9
gene UNIPROT WIPF2
gene UNIPROT CFLAR
gene UNIPROT FHL5
gene UNIPROT SERPINA3
disease MESH genetic disorders
disease MESH tumors
pathway BSID Release

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *